Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
US8178693 | ARRAY BIOPHARMA INC | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(1 year, 16 days ago) | |
US7777050 | ARRAY BIOPHARMA INC | N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2025
(11 months from now) | |
US9562016 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(9 years from now) | |
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8513293 | ARRAY BIOPHARMA INC | Methods of treating a hyperproliferative disorder or inhibiting cell growth in a mammal |
Mar, 2023
(1 year, 16 days ago) | |
US8193229 | ARRAY BIOPHARMA INC | Method of treatment using N3 alkylated benzimidazole derivatives as MEK inhibitors |
Mar, 2023
(1 year, 16 days ago) | |
US9850229 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
US10005761 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
US9593100 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Aug, 2030
(6 years from now) | |
US9314464 | ARRAY BIOPHARMA INC | Compounds and compositions as protein kinase inhibitors |
Jul, 2031
(7 years from now) | |
US9598376 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(9 years from now) | |
US9980944 | ARRAY BIOPHARMA INC | Preparation of and formulation comprising a MEK inhibitor |
Oct, 2033
(9 years from now) |
Mektovi is owned by Array Biopharma Inc.
Mektovi contains Binimetinib.
Mektovi has a total of 11 drug patents out of which 3 drug patents have expired.
Expired drug patents of Mektovi are:
Mektovi was authorised for market use on 27 June, 2018.
Mektovi is available in tablet;oral dosage forms.
Mektovi can be used as indicated in combination with encorafenib for the treatment of melanoma mediated by a b-raf protein kinase, indicated in combination with encorafenib for the treatment of melanoma, treatment of melanoma with a braf mutation, indicated in combination with encorafenib for the treatment of melanoma with a braf mutation, method of treating melanoma.
The generics of Mektovi are possible to be released after 18 October, 2033.
Drug Exclusivity | Drug Exclusivity Expiration |
---|---|
Orphan Drug Exclusivity (ODE) | Jun 27, 2025 |
New Indication (I) | Oct 11, 2026 |
Drugs and Companies using BINIMETINIB ingredient
Market Authorisation Date: 27 June, 2018
Treatment: Indicated in combination with encorafenib for the treatment of melanoma; Method of treating melanoma; Indicated in combination with encorafenib for the treatment of melanoma with a braf mutation; Indi...
Dosage: TABLET;ORAL